Acutaas Chemicals Ltd.

₹1,862.4

134.4 (7.8%)

ACUTAAS Share Price

Pharmaceuticals & Biotechnology

As on January 28, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 15,256 Cr

P/E Ratio192.14

Dividend Yield0.02 %

Trendline Performance

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	1,698.14	Bullish
10-DMA	1,689.23	Bullish
20-DMA	1,707.14	Bullish
50-DMA	1,707.85	Bullish
100-DMA	1,630.26	Bullish
200-DMA	1,407.73	Bullish

Historical Performance

1 Year

97.9%

3 Years

323.9%

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	10,069	7,175	6,167	5,201	3,406
Total Expenditure	7,748	5,890	4,941	4,150	2,605
Other Income	169	75	43	28	14
Operating Profit	2,490	1,360	1,269	1,079	815
Interest	62	59	24	64	56
Depreciation	266	161	123	101	42
Profit Before Tax	2,162	819	1,122	915	717
Consolidated Net Profit	1,587	428	833	719	540
Adjusted EPS	10	6	11	10	3

Compounded Sales Growth

10 Years:45.6

5 Years:33.3

3 Years:14.1

TTM:7

Compounded Profit Growth

10 Years:65.8

5 Years:42

3 Years:17.1

TTM:30

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:61.8

TTM:65

Return on Equity

10 Years:2

5 Years:2.9

3 Years:11.4

last year:9.7

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	409	369	364	364	315
Total Reserves	12,686	6,348	5,575	4,858	1,354
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	269	1,280	101	73	803
Other Current Liabilities	135	648	66	49	346
Short Term Borrowings	82	726	28	---	445
Total Liabilities	15,493	10,959	7,669	6,589	4,133
Capital Work in Progress	1,303	1,254	255	19	2
Long Term Loans & Advances	559	486	172	142	17
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	692	725	411	431	208
Total Current Assets	7,916	4,933	4,571	4,296	2,162
Total Assets	15,493	10,959	7,669	6,589	4,133
Adjusted Book Value	80	91	82	143	17

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 192.14, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 62.2%, indicating sustained price appreciation.
The stock carries a high beta of 1.4, implying higher volatility and elevated risk.
In the last financial year, the company reported an EBITDA of ₹2490 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹10069 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1649455.3

No. of Shares: 886 (Approx)

Performance:64.9%

P/L: ₹649455.3

NIFTY Performance: 9.4%

1 day Top Gainers